Goldman Sachs Downgrades Valneva SE (VLA:FP) (VALN) to Sell Apr 22, 2026 12:53AM
Goldman Sachs Downgrades Valneva SE (VALN) to Sell Apr 22, 2026 12:53AM
Valneva SE (VALN) PT Lowered to $11 at Guggenheim Apr 16, 2026 07:44AM
Valneva SE (VLA:FP) (VALN) PT Lowered to EUR8.50 at Stifel Mar 24, 2026 08:34AM
Jefferies on Valneva SE (VALN): path to approval intact, 'weakness presents buying oppty' Mar 23, 2026 03:13PM


Sep 8, 2025 07:22AM Valneva SE (VALN) PT Lowered to $13 at Guggenheim
Aug 25, 2025 10:50AM Valneva SE (VALN) PT Lowered to $14 at Jefferies
Aug 22, 2025 02:49PM Valneva SE (VALN) Halted, News Pending
Aug 19, 2025 06:41AM H.C. Wainwright Assumes Valneva SE (VALN) at Buy
Jun 19, 2025 11:00AM Valneva Selects CliniOps as the Technology Partner for Multiple Post-Marketing Studies to Support the IXCHIQ Chikungunya Vaccination Program in Brazil
Apr 10, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Valneva SE (VALN)
Feb 19, 2025 06:57AM Valneva SE (VALN) PT Lowered to $17 at H.C. Wainwright
Feb 6, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Valneva SE (VALN)
Jan 22, 2025 11:46AM Valneva (VALN) Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
Oct 16, 2024 11:47AM Valneva SE (VALN) and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V
Oct 11, 2024 06:34AM Valneva SE (VALN) PT Lowered to $20 at H.C. Wainwright
Sep 25, 2024 06:38AM Valneva SE (VALN) PT Lowered to $23 at H.C. Wainwright
Sep 4, 2024 07:35AM H.C. Wainwright Reiterates Buy Rating on Valneva SE (VALN)
Jul 1, 2024 06:40AM H.C. Wainwright Reiterates Buy Rating on Valneva SE (VALN)